相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Joseph Meserve et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh et al.
DRUG SAFETY (2019)
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
Byong Duk Ye et al.
LANCET (2019)
Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience
P. Wils et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders
Robert P. Hirten et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Lydia C. T. Buer et al.
INFLAMMATORY BOWEL DISEASES (2018)
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience
Gary R. Lichtenstein et al.
INFLAMMATORY BOWEL DISEASES (2018)
Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics
Eric J. Mao et al.
BMJ OPEN GASTROENTEROLOGY (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
The safety of ustekinumab for the treatment of psoriatic arthritis
A. Lopez-Ferrer et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
Magali Lemaitre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
Eddie Y. Liu et al.
CASE REPORTS IN MEDICINE (2017)
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
R. Khanna et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
Kelvin T. Thia et al.
GASTROENTEROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2007)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Risk factors for surgery and postoperative recurrence in Crohn's disease
O Bernell et al.
ANNALS OF SURGERY (2000)
分享论文
